A rapid stability-indicating, fused-core HPLC method for simultaneous determination of β-artemether and lumefantrine in anti-malarial fixed dose combination products

BACKGROUND: Artemisinin-based fixed dose combination (FDC) products are recommended by World Health Organization (WHO) as a first-line treatment. However, the current artemisinin FDC products, such as β-artemether and lumefantrine, are inherently unstable and require controlled distribution and stor...

Descripción completa

Detalles Bibliográficos
Autores principales: Suleman, Sultan, Vandercruyssen, Kirsten, Wynendaele, Evelien, D’Hondt, Matthias, Bracke, Nathalie, Duchateau, Luc, Burvenich, Christian, Peremans, Kathelijne, De Spiegeleer, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651282/
https://www.ncbi.nlm.nih.gov/pubmed/23631682
http://dx.doi.org/10.1186/1475-2875-12-145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651282/
https://www.ncbi.nlm.nih.gov/pubmed/23631682
http://dx.doi.org/10.1186/1475-2875-12-145

Ejemplares similares